论文部分内容阅读
目的观察泮托拉唑钠肠溶胶囊治疗胃溃疡的临床疗效。方法将110例胃溃疡患者随机分为观察组和对照组各55例,对照组实施常规的抗幽门螺杆菌治疗,观察组则在对照组基础上添加泮托拉唑胶囊治疗,比较2组的治疗效果、幽门螺杆菌清除率、症状积分及并发症情况。结果观察组总有效率为92.73%高于对照组的76.36%,差异有统计学意义(χ~2=8.406,P<0.05);幽门螺杆菌清除率为98.18%高于对照组的85.45%,差异有统计学意义(P<0.05)。治疗前2组的症状积分无统计学差异(P>0.05),经治疗后2组的各症状积分均降低,且观察组的评分低于对照组,差异均有统计学意义(P<0.05)。2组的不良反应发生率无统计学差异(χ2=1.450,P>0.05)。结论应用泮托拉唑治疗胃溃疡可提高幽门螺杆菌的清除率、更好地改善患者的临床症状,且药物的安全性高,应在临床推广应用。
Objective To observe the clinical efficacy of pantoprazole sodium enteric-coated capsules in the treatment of gastric ulcer. Methods 110 patients with gastric ulcer were randomly divided into the observation group and the control group of 55 cases, the control group of conventional anti-Helicobacter pylori treatment, the observation group was added to the control group on the basis of pantoprazole capsules, compared with two groups Therapeutic efficacy, Helicobacter pylori clearance, symptom scores and complications. Results The total effective rate in the observation group was 92.73%, which was significantly higher than that in the control group (76.36%, χ ~ 2 = 8.406, P <0.05). The clearance rate of Helicobacter pylori was 98.18% higher than that of the control group (85.45% The difference was statistically significant (P <0.05). There was no significant difference in symptom scores between the two groups before treatment (P> 0.05). After treatment, the score of each symptom in both groups decreased, and the score of the observation group was lower than that of the control group (P <0.05) . There was no significant difference in adverse reaction between the two groups (χ2 = 1.450, P> 0.05). Conclusion The application of pantoprazole in the treatment of gastric ulcer can improve the clearance rate of Helicobacter pylori, and improve the clinical symptoms of patients better. And the drug is safe and should be popularized and applied clinically.